Depression is characterized by high prevalence, high disability rate, high recurrence rate, and data from the World Health Organization show that about 3.
8% of the global population suffers from depression
.
At present, with the rapid development of the global economy and society, the pace of life and work pressure of residents have increased, and the number of people suffering from psychological and behavioral problems and mental disorders is gradually increasing
.
It is worth noting that with the increase in prevalence and awareness, the antidepressant industry has also developed rapidly
in recent years.
IQVIA data shows that the market share of antidepressants in China has reached 6.
31 billion yuan
in 2020.
According to Zhongkang CMH data, data from the two channels of secondary and above public hospitals and retail pharmacies in the country in 2021 show that the sales scale of antidepressants in 2021 has also exceeded 8 billion yuan
.
Good market prospects will naturally attract many pharmaceutical companies to rush to develop antidepressants
.
Recently, Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, said that in a Phase 3b trial, the company's esketamine nasal spray Spravo was better than AstraZeneca's quetiapine sustained-release Seroquel
in the treatment of adult patients with refractory major depressive disorder (TRD).
It is understood that 676 adults with TRD participated in the study, called ESCAPE-TRD, who received either Spravato (n=336) or quetiapine XR (n=340).
Results at week 8 showed that 27.
1% of patients in the Spavato group were in remission, compared to 17.
6%
in the quetiapine XR group.
In fact, for a long time, multinational pharmaceutical companies have had huge advantages in the research and development of antidepressants, and while achieving more and more results, they are accelerating innovation
.
It is reported that in China, in the past, almost all antidepressants were developed
by multinational pharmaceutical companies.
However, in recent years, due to the increase in the number of patients, the continuous expansion of market scale, and the pressure of centralized procurement, many local companies have also begun to differentiate the layout of innovative drugs in the field of psychiatric and neurological devices
.
Since 2022, a large number of domestic pharmaceutical companies' antidepressant drugs have received good news
that they have been approved for marketing.
For example, on November 23, the marketing application of vothioxetine hydrobromide tablets submitted by Shandong Jingwei Pharmaceutical with generic Type 4 was accepted by CDE
.
According to the data, vothioxetine hydrobromide tablets are antidepressants, and the global sales of the original drug exceeded 1 billion US dollars
in 2021.
Vothioxetine hydrobromide tablets were jointly developed by Lundbeck Pharmaceutical and Takeda Pharmaceutical in Denmark for the treatment of depression
in adults.
The original drug was launched in the United States in November 2013, approved for entry into China in 2017, and its global sales exceeded US$1 billion
in 2021.
On November 3, the State Food and Drug Administration released news that it approved the marketing of the Class 1 innovative drug Toludi venlafaxine hydrochloride sustained-release tablets (trade name Ruoxinlin) declared by Shandong Luye Pharmaceutical Co.
, Ltd.
(hereinafter referred to as Luye Pharmaceutical), which is an innovative drug independently developed by China and has independent intellectual property rights, suitable for the treatment
of depression.
In June, Yongtai Technology issued an announcement that its subsidiary Zhejiang Yongtai Pharmaceutical was approved for imitating the enteric-coated capsules of the antidepressant duloxetine hydrochloride reported for production in Class 4, which was regarded as a review; In May, Jiangsu Haosen Pharmaceutical's vothioxetine hydrobromide tablets were approved for marketing, which was officially approved to enter China as early as 2017 for the treatment of adult depression.
.
.
From the current point of view, with the continuous layout of local pharmaceutical companies, the competition pattern of domestic antidepressants has begun to change
.
However, at the same time, the industry also proposed that the "fierce battle" in the domestic antidepressant market in the future will not only be limited to the competition between existing generic drug products and original drugs, but also a new round of "fierce battle"
with the successive launch of a new generation of antidepressants under development.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
